02269.HK
WuXi Biologics (Cayman) Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 44.48
−1.29%Year over year
Reported trailing growth
- Revenue
- +17.8%
- EBITDA
- +24.4%
- EBIT
- +30.0%
- EPS
- +19.8%
- Free cash flow
- +151.5%
- Operating cash flow
- +58.2%
Forward estimates
Based on analyst estimates
- Revenue
- -40.2%
- EBITDA
- -45.5%
- EPS
- -38.8%
Three-year CAGR
- Revenue
- +12.6%
- EBITDA
- +10.4%
- EBIT
- +15.2%
- Net income
- +3.6%
- EPS
- +3.1%
- Free cash flow
- +153.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026